Last updated: September 3, 2026

Thiopental sodium is a mature, off-patent intravenous barbiturate anesthetic with limited commercial value and a fragmented supply base. Its financial trajectory has been driven by loss of exclusivity, manufacturing exits, regulatory controls, and substitution by propofol, etomidate, ketamine, and inhaled anesthetics. Public companies generally do not report thiopental revenue separately, and no reliable global product-level sales estimate is publicly available.

What is the current market position of thiopental sodium?

Thiopental sodium is a legacy injectable anesthetic used mainly for induction of general anesthesia, rapid seizure control, and selected neurocritical-care applications. Its use has declined substantially in high-income markets, where propofol and etomidate are more commonly selected for routine induction.

The drug remains clinically relevant in specific settings:

Induction of anesthesia when a barbiturate is preferred.
Refractory status epilepticus.
Intracranial hypertension and cerebral metabolic suppression.
Veterinary anesthesia in certain jurisdictions.
Resource-constrained hospitals where alternative agents are unavailable or more expensive.
Specialized military, emergency, or critical-care protocols.

The market is no longer a conventional branded pharmaceutical market. It is a low-volume, procurement-driven market in which hospital tenders, national shortages, controlled-substance requirements, and manufacturing reliability matter more than brand differentiation.

When did thiopental sodium lose exclusivity?

Thiopental sodium lost meaningful patent exclusivity decades ago. The active ingredient was introduced in the 1930s, and any basic composition-of-matter patents have long expired. Current commercial barriers are regulatory and operational rather than patent-based.

Market characteristic	Current position
Active ingredient	Thiopental sodium
Original commercial period	1930s onward
Composition patent position	Expired
Regulatory status	Legacy prescription injectable drug
Primary dosage form	Sterile powder for reconstitution
Current competition	Propofol, etomidate, ketamine, pentobarbital and inhaled anesthetics
Commercial differentiation	Supply reliability, price, tender access and regulatory compliance
Patent-based generic entry risk	Low

There is no commercially meaningful active patent estate protecting thiopental sodium as a molecule. Any remaining intellectual-property value would more likely involve manufacturing processes, packaging, formulation stability, delivery systems, or use-specific technology. Those rights would not recreate exclusivity around the core drug.

What patents protect thiopental sodium products?

No active, broad patent protection is expected to cover the thiopental sodium active ingredient in major pharmaceutical markets. The drug is a small-molecule generic with a long history of use.

Potentially relevant rights could include:

Sterile manufacturing processes.
Improved powder stability.
Container-closure systems.
Reconstitution devices.
Combination anesthesia protocols.
Specific medical-use claims.

These rights would have limited commercial value unless they controlled a required manufacturing step or a differentiated delivery system. Conventional thiopental sodium powder for injection is unlikely to support premium pricing through patent protection.

The principal competitive risk is therefore not a Paragraph IV patent challenge. Generic manufacturers can generally enter based on approval, manufacturing capability, and supply-chain access rather than by invalidating or circumventing an active innovator patent.

What is the FDA regulatory status of thiopental sodium?

Thiopental sodium has a long-standing FDA regulatory history, but U.S. availability has been disrupted by manufacturing and supply problems. FDA records distinguish commercial discontinuation caused by business or supply decisions from withdrawal caused by safety or effectiveness concerns.

The U.S. market experienced a major supply disruption after Hospira stopped producing thiopental sodium in 2011. FDA identified the disruption as a supply issue rather than a determination that the drug was unsafe or ineffective (U.S. Food and Drug Administration, 2011).

The regulatory implications are significant:

A product may remain an approved legacy drug while being commercially unavailable.
FDA approval does not guarantee continuous supply.
Importation or temporary alternative sourcing can become relevant during shortages.
Hospital use depends on validated suppliers and controlled-substance compliance.
Re-entry requires manufacturing, quality, labeling and distribution capabilities.

FDA’s Drug Shortages database and discontinued-drug records are more useful for assessing practical availability than historical approval status alone.

What is the Orange Book status of thiopental sodium?

Thiopental sodium has no meaningful Orange Book exclusivity profile comparable with newer branded drugs. Any historical reference product or abbreviated new drug application listing must be evaluated against current commercial status because several legacy injectable products have been discontinued or are no longer actively marketed.

The likely commercial interpretation is:

No unexpired new chemical entity exclusivity.
No commercially important orphan exclusivity.
No current blockbuster reference-product position.
No meaningful listed-patent barrier for routine thiopental sodium injection.
Product-specific approval and manufacturing status remain more important than Orange Book patent listings.

For generic applicants, the practical challenge is not patent litigation. It is demonstrating product quality, sterility, stability, bioequivalence where applicable, and reliable controlled-substance manufacturing.

Why did thiopental sodium supply contract?

The U.S. supply contraction was linked to manufacturing economics and dependence on a limited number of active pharmaceutical ingredient suppliers. Hospira’s 2011 discontinuation removed a major commercial source and exposed the market’s low redundancy (U.S. Food and Drug Administration, 2011).

Several factors reduced supplier participation:

Low revenue per manufacturing line

Thiopental sodium is generally sold as a low-cost injectable. The product requires sterile manufacturing, validated filling, quality testing, controlled distribution and inventory management. Those costs are difficult to recover in a low-volume market.

Limited pricing power

Hospitals often purchase thiopental sodium through tenders or group purchasing organizations. Price competition limits the ability to pass higher raw-material, labor, compliance or logistics costs to buyers.

Controlled-substance obligations

In the United States, thiopental is subject to controlled-substance requirements. DEA registration, inventory controls, recordkeeping, security and diversion prevention add operating costs (U.S. Drug Enforcement Administration, n.d.).

Demand substitution

Propofol became the dominant alternative for many routine induction procedures. Etomidate is commonly selected when cardiovascular stability is prioritized, while ketamine has expanded in emergency and hemodynamically unstable patients. Reduced routine demand makes fixed manufacturing costs harder to support.

Global fragmentation

Availability differs sharply by country. A product can remain listed in national formularies while being difficult to procure. Suppliers often serve narrow geographic markets, and the economics depend on local tender structures and hospital demand.

How does thiopental sodium compare with competing anesthetics?

Drug	Main commercial role	Advantages over thiopental	Limitations
Propofol	Routine induction and maintenance	Rapid recovery, broad familiarity, extensive supply	Hypotension, pain on injection, lipid formulation logistics
Etomidate	Induction in hemodynamic instability	Relative cardiovascular stability	Adrenal suppression, myoclonus
Ketamine	Emergency, trauma and procedural anesthesia	Analgesia, sympathetic stimulation, multiple dosage forms	Emergence reactions, variable hemodynamic effects
Pentobarbital	Seizure control and specialized uses	Established barbiturate alternative	Sedation, respiratory depression, limited routine anesthesia use
Thiopental	Legacy induction and neurocritical care	Rapid onset, cerebral metabolic suppression, long clinical history	Supply instability, prolonged recovery, respiratory and cardiovascular depression

Thiopental retains a niche where clinicians value its rapid onset and cerebral effects. It is less competitive for routine elective anesthesia because propofol offers a more favorable recovery profile and has a deeper commercial supply base.

What is the financial trajectory of thiopental sodium?

The financial trajectory is best described as long-term structural decline with episodic shortage-driven pricing pressure.

Period	Financial and market trend
1930s-1980s	Branded anesthetic market with strong clinical adoption
1990s-2000s	Generic erosion and substitution by propofol
2011	Major U.S. supply disruption after Hospira discontinuation
2010s	Fragmented international supply and recurring procurement concerns
2020s	Niche demand, low-volume manufacturing and limited public revenue disclosure

No major manufacturer publicly reports thiopental sodium as a standalone revenue category. For generic suppliers, sales are likely immaterial relative to broader anesthesia, injectable, hospital or specialty-pharmaceutical portfolios.

Revenue is concentrated in:

Institutional hospital contracts.
Government and military procurement.
Emergency reserve purchases.
Specialty critical-care demand.
Veterinary channels in selected markets.
Markets where propofol access or affordability is constrained.

Shortages can create temporary price increases, but shortage pricing does not necessarily translate into attractive long-term margins. Buyers may reduce use, switch products, or impose substitution protocols once alternatives are available.

Which companies are challenging or supplying thiopental sodium?

The competitive field is composed of generic and specialty injectable manufacturers rather than branded innovators. Historic U.S. supply included Abbott and Hospira-associated products. International availability has involved regional manufacturers and hospital-supply companies, with product status varying by jurisdiction.

A reliable global ranking of current thiopental suppliers is not available from public company disclosures. Supplier identification requires country-specific regulatory databases and procurement records because manufacturers may:

Hold an approval without active commercial distribution.
Supply only government or hospital channels.
Market under different product names.
Sell through distributors rather than directly.
Maintain intermittent production based on tender awards.

The commercial landscape is therefore fragmented and difficult to measure through standard prescription-sales data.

What generic entry risks exist for thiopental sodium?

Patent-related generic entry risk is low because the core molecule is long off-patent. The main risks are operational.

Manufacturing barriers

Sterile injectable production requires:

Validated aseptic processing.
Reliable active pharmaceutical ingredient supply.
Sterility assurance.
Low-endotoxin controls.
Stability data for the reconstituted product.
Controlled-substance compliance where applicable.
Adequate inventory to meet hospital tenders.

Regulatory barriers

A new entrant may face:

Product-specific FDA or national approval requirements.
Facility inspection requirements.
Drug-master-file or API qualification issues.
Labeling requirements for controlled substances.
Shortage-related import or supply restrictions.
Pharmacovigilance and recall obligations.

Commercial barriers

A new supplier must secure hospital contracts and demonstrate uninterrupted delivery. Buyers may resist switching because thiopental is used in high-acuity settings where product familiarity and supply continuity are important.

What patent litigation and Paragraph IV activity affect thiopental sodium?

No major current Paragraph IV litigation is associated with the core thiopental sodium market. The molecule’s age and generic status make conventional patent litigation commercially unlikely.

Litigation exposure is more likely to arise from:

Product liability.
Manufacturing deviations.
Drug shortages.
Procurement disputes.
Controlled-substance compliance.
Contracting and distribution issues.
Labeling or regulatory enforcement.

The absence of meaningful patent litigation does not eliminate market risk. It shifts the risk profile from legal exclusivity to manufacturing continuity and regulatory execution.

What licensing deals affect thiopental sodium?

There is no widely disclosed current licensing transaction that materially changes the global thiopental sodium market. Historical rights transfers and distributor arrangements have occurred, but public financial terms are generally unavailable.

Potential deal structures are more likely to involve:

Regional marketing rights.
Contract manufacturing.
API supply agreements.
Government procurement.
Hospital-distribution arrangements.
Temporary shortage sourcing.

The low value of the underlying molecule limits the likelihood of large upfront payments or royalty-bearing strategic alliances.

How strong is the thiopental sodium patent estate?

The patent estate is weak from an exclusivity perspective but may be defensible from a manufacturing-compliance perspective.

Dimension	Assessment
Active ingredient patents	Very weak or expired
Method-of-use patents	Limited commercial relevance
Formulation patents	Potentially narrow and product-specific
Device patents	Possible but not central to standard products
Manufacturing know-how	Relevant, especially for sterile powder
Regulatory exclusivity	None of practical commercial significance
Litigation leverage	Low
Supply-chain leverage	Potentially high during shortages

The product’s real barrier to entry is execution. A manufacturer that can produce compliant sterile injectable product reliably may obtain meaningful institutional business despite the absence of patent protection.

What is the outlook for thiopental sodium revenue?

Base-case revenue is likely to remain flat to declining in mature anesthesia markets. Growth is unlikely without a supply disruption affecting competing anesthetics or a regulatory change that expands use.

Base case

Thiopental remains a niche hospital product. Volumes decline gradually as propofol and other alternatives retain routine-use share. Pricing remains constrained by tenders.

Upside case

A shortage of propofol, etomidate or ketamine increases thiopental demand. Suppliers with approved facilities and available inventory capture temporary volume and pricing benefits.

Downside case

Additional manufacturers exit, hospitals remove thiopental from formularies, and clinicians shift permanently to alternatives. The product remains approved in some countries but becomes commercially unavailable in others.

The strongest commercial opportunity is not a branded launch. It is dependable supply in markets where hospitals maintain thiopental on emergency or critical-care formularies.

Key Takeaways

Thiopental sodium is a mature, off-patent injectable anesthetic with no meaningful core-molecule exclusivity.
The U.S. market suffered a major supply disruption after Hospira discontinued production in 2011.
Public companies do not generally disclose thiopental revenue separately.
Financial value is limited by low pricing, declining routine use and expensive sterile manufacturing.
Propofol, etomidate and ketamine are the main competitive substitutes.
Generic entry risk is operational rather than patent-driven.
Formulation, method-of-use and device patents have limited ability to create durable market exclusivity.
The best commercial position belongs to suppliers with dependable sterile manufacturing, regulatory approvals and institutional distribution.
Long-term revenue is likely to remain niche, with temporary upside during shortages.

FAQs About Thiopental Sodium Market Economics

Is thiopental sodium still commercially available in the United States?

Availability has been inconsistent and depends on current supplier, regulatory and shortage conditions. Historical FDA records document significant commercial discontinuation and supply disruption, particularly after the 2011 Hospira exit.

Does thiopental sodium have generic competition?

Yes. The active ingredient is long off-patent, and competition comes from generic and regional injectable manufacturers. Market access depends more on approval and supply capability than on patent clearance.

Can a new manufacturer obtain premium pricing for thiopental sodium?

Only temporarily in shortage conditions or specialized procurement channels. Routine pricing is constrained by hospital tenders and substitution by propofol, etomidate and ketamine.

Is thiopental sodium used more in anesthesia or seizure treatment?

Historically, anesthesia was the principal use. Current demand is more concentrated in selected anesthetic, neurocritical-care and refractory-seizure applications, depending on local clinical practice.

What is the most important investment risk in thiopental sodium?

The central risk is insufficient market scale to support reliable sterile manufacturing. Supply interruption, not patent expiry, is the dominant commercial risk.

References

U.S. Drug Enforcement Administration. (n.d.). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling
U.S. Food and Drug Administration. (2011). FDA drug safety communication and drug shortage information relating to thiopental sodium injection. https://www.fda.gov/drugs/drug-safety-and-availability
U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.). Discontinued drugs. https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files
World Health Organization. (2019). WHO model list of essential medicines: 21st list. World Health Organization. https://www.who.int/publications/i/item/WHOMVPEMPIA2019.06

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	14
DailyMed Link:	THIOPENTAL SODIUM at DailyMed

Sponsor	Phase
Ain Shams University	Early Phase 1
Ain Shams University	N/A
Konkuk University Medical Center	N/A

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	PENTOTHAL	thiopental sodium	SUSPENSION;RECTAL	011679-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Summary for THIOPENTAL SODIUM

Recent Clinical Trials for THIOPENTAL SODIUM

Medical Subject Heading (MeSH) Categories for THIOPENTAL SODIUM

Anatomical Therapeutic Chemical (ATC) Classes for THIOPENTAL SODIUM